Related Experiment Videos
Cerebellar myeloblastoma formation in CD7-positive, neural cell adhesion molecule (CD56)-positive acute myelogenous
Y Hatano1, I Miura, T Horiuchi
1Third Department of Internal Medicine, Akita University School of Medicine, Japan.
Abstract:
We present a first report of a CD7+ acute myelogenous leukemia patient who developed intracranial myeloblastomas. The patient was neurologically normal on physical examination at presentation. The peripheral leukocyte count was extremely high (203.6 x 10(9)/l). The blasts expressed CD7 and CD56 (neural cell adhesion molecule) in addition to CD13, CD33, CD34, and HLA-DR. The karyotype of bone marrow cells was normal. The patient was diagnosed as having acute myelogenous leukemia (AML, M1). Following a short period of complete remission, bone marrow relapse and meningeal leukemia occurred, and the patient died of respiratory failure. Autopsy revealed that blasts had invaded the subarachnoid space and cerebellum, and two myeloblastomas were found in the cerebellar hemisphere. Both CD7+ and CD56+ AML have been reported to have a high incidence of central nervous system involvement. CD7+ CD56+ AML calls for prophylaxis of central nervous system leukemia.
Insights
This study reports the first case of CD7+ acute myelogenous leukemia (AML) with intracranial myeloblastomas. CD7+ CD56+ AML necessitates central nervous system leukemia prophylaxis due to high risk.
Area of Science:
- Hematology
- Neurology
- Oncology
Background:
- Acute myelogenous leukemia (AML) is a heterogeneous malignancy.
- Central nervous system (CNS) involvement in AML, while uncommon, portends a poor prognosis.
- CD7 and CD56 expression on AML blasts are associated with specific clinical features and outcomes.